Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Booster Immunogenicity Study of S-268023 vs COMIRNATY XBB.1.5 in Adults in Japan
jRCT2031230503Phase 3Active, not recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Dec 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of S-268023 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: SARS-CoV-2 neutralizing antibody geometric mean titer (GMT) on day 29 against XBB.1.5 variant and Seroresponse rate on day 29 against XBB.1.5 variant. Started Dec 2023; status: active, not recruiting.
02
Drugs
S-268023
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031230503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230503.